Concomitant genetic alterations are associated with response to EGFR targeted therapy in patients with lung adenocarcinoma.

ABSTRACT:

Background

Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are considered to be more effective than chemotherapy in the treatment of EGFR-mutant advanced non-small cell lung cancer (NSCLC). However, in addition to EGFR-sensitive mutations, the genetic factors that affect the prognosis of patients who receive TKI treatment are not yet clear.

Methods

The clinical data of 36 NSCLC patients with EGFR mutation who received TKI treatment were retrospectively analyzed. Liquid re-biopsy with next generation sequencing (NGS) analysis was performed to analyze genetic alterations and potential resistance mechanisms.

Results

All of the patients harbored actionable sensitive EGFR mutations by NGS, with the major types being 19del or 21L858R (52.78%, 19/36 a

SUBMITTER: Chen H 

PROVIDER: S-EPMC7481595 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature